Skip to content
Get in touch
Menu
RAW Molecular Systems
Gut Microbiome + Metabolome Report
Sample: Jordan A.
ID: RAW-2K7F-0194
Collected: Jun 28, 2026 · Reported: Jul 12, 2026
Gut balance score
DYSBIOSIS EUBIOSIS
61/100
Moderate imbalance

Your gut is moderately out of balance — and it's addressable.

Your community skews toward lower diversity with a below-target supply of the short-chain fatty acids that calm the gut lining and train your immune system. A few beneficial workhorses are running low while some inflammation-associated groups are elevated. The good news: the biggest levers here — fiber, polyphenols, and a few foods to ease off — are ones you control. Re-test in 8–12 weeks to see the shift.

Diversity (Shannon)
3.1
Below range
SCFA index
Low
Butyrate limited
Inflammation signal
Elevated
Watch
Barrier integrity
Reduced
Support
Key taxa · who's living in your gut

Beneficial — running low

Faecalibacterium prausnitziiLow
Butyrate producer · anti-inflammatory · dashed band = typical healthy range
Akkermansia muciniphilaLow
Mucus-layer & metabolic health · GLP-1 friendly
Roseburia spp.Low-normal
Butyrate producer · fiber-fed
Bifidobacterium spp.In range
Immune tolerance · Treg support

Inflammation-associated — elevated

Proteobacteria (incl. E. coli)High
Bloom associated with dysbiosis & barrier stress
Prevotella copriElevated
Linked in research to new-onset inflammatory arthritis
Ruminococcus gnavusElevated
Associated with IBD activity & inflammation
Enterobacteriaceae (broad)Elevated
Gram-negative · LPS / endotoxin source
Metabolite panel · what they're making

Short-chain fatty acids

ButyrateLow · 6.2 µmol/g
PropionateLow-normal · 11 µmol/g
AcetateNormal · 48 µmol/g
Total SCFABelow target

Inflammation & barrier

LPS / endotoxin signalElevated
Calprotectin (proxy)Upper-normal
Secondary : primary bile acidsShifted
Branched-chain fatty acidsElevated
+ 188 additional metabolites measured — full table in your downloadable report.
Metabolic & GLP-1 context
38% OF TARGET

Your SCFA profile suggests below-target support for your own GLP-1

GLP-1 is released by your gut in response to short-chain fatty acids — and yours are running low, driven by reduced butyrate producers. Raising fiber and SCFA output is the lever most likely to help. If you're on a GLP-1 medication, this is your baseline: re-test to confirm your diversity and SCFAs are holding as your appetite and intake change. Discuss with your clinician

Systemic signals · wellness context
Gut inflammation
Elevated signal
Metabolic support
Needs attention
Barrier / "leaky gut"
Reduced
Immune tolerance
Adequate
Overall diversity
Below range

Signals are educational indicators derived from your microbial and metabolite data — not diagnoses.

Personalized food guidance · from your data

Favor — likely to calm your gut

  • Fiber diversity: oats, barley, legumes, lentils
  • Resistant starch: cooked-and-cooled potato, green banana
  • Polyphenols: berries, extra-virgin olive oil, green tea, cocoa
  • Prebiotics: onion, garlic, leek, asparagus, chicory
  • Fermented: yogurt, kefir, sauerkraut, kimchi
  • Omega-3: oily fish, walnuts, flax

Ease off — likely to flare your gut

  • Emulsifiers: polysorbate-80, carboxymethylcellulose your data
  • Ultra-processed & high-additive packaged foods
  • Excess added sugar & refined carbohydrate
  • Very high red / processed meat frequency
  • Artificial sweeteners (sucralose, saccharin) — trial & recheck
  • Alcohol beyond light intake
Track over time

This is your baseline.

Re-test in 8–12 weeks to see your balance score, diversity, and SCFAs respond to the changes above. Your trend line builds with each report.

Order a re-test
Now (61) Re-test Goal
Your own report

Get your own gut report.

One at-home sample — 200,000 microbial features and 200 metabolites, read and explained in plain language.

Get your kit — $50About the gut test

Sample report. All values shown are illustrative and do not represent a real individual or result.

RAW reports provide wellness and educational insights into your microbiome and metabolites. They are not intended to diagnose, treat, cure, or prevent any disease and are not a substitute for professional medical advice. Conditions such as IBD, inflammatory arthritis, obesity, and allergic disease are diagnosed and managed by a qualified healthcare provider. Do not start, stop, or change any medication — including GLP-1 medications — based on this report. Reference ranges are population-based and evolving; individual results vary. These statements have not been evaluated by the FDA.